The aim of our study was to retrospectively analyze impact of BCL-2 expression on the outcome of a cohort of elderly AML patients, treated with intensive chemotherapy or HMAs, and the association with other clinical and laboratory characteristics possibly identifying subsets of patients taking higher advantage from BCL-2 inhibition. Here, BCL2 is linked to acute myeloid leukemia.